Blog

February 3, 2025

SCOPE Summit 2025: Fast Forward to 2035: What Success Could Look Like in Converging Clinical Research and Care—And How to Get There

This year’s SCOPE conference in Orlando kicked off with a keynote address from Janice Chang, CEO, TransCelerate Biopharma, and Mark McClellan, MD, PhD, director, Duke-Margolis Institute for Health Policy, Former Commissioner, FDA. Titled “Fast Forward to 2035: What Success Could Look Like in Converging Clinical Research and Care—And How to Get There”, the duo discussed…

Explore

December 9, 2024

A New Era in Advancing Care for Pregnant and Breastfeeding Patients

One major challenge facing the clinical research ecosystem is not whether, but how to study drug safety and efficacy in pregnant and breastfeeding populations. A growing number of organizations—including the ICH E21 Expert Working Group (EWG) and TransCelerate’s Interpretation of Pharmacovigilance Guidances & Regulations  (IGR PV) initiative—are diligently seeking ethical and responsible solutions to protect these…

Explore

October 10, 2024

Improving Medicine Use During Pregnancy & Breastfeeding: Forging a Path Forward   

The scientific community intended to protect pregnant and breastfeeding populations when it strictly limited their involvement in clinical trials after the thalidomide crisis of the 1950s-1960s. Yet over the past few decades, people have increasingly recognized the real-life challenges posed by the lack of research into the safety of medications used during pregnancy and breastfeeding.…

Explore

August 16, 2024

Transforming Pharmacovigilance: Solutions to Solve Regulatory Challenges

Patient safety depends partly on sponsor organizations’ compliance with pharmacovigilance (PV) regulatory requirements—even when global variations exist. Helping sponsors interpret and operationalize challenging PV regulations and guidances is the goal of TransCelerate’s Interpretation of Pharmacovigilance Guidances & Regulations (IGR PV) initiative. In this third installment of our IGR PV blog series, we will examine the solutions…

Explore

June 26, 2024

A COO’s Insights: Perspectives from the DIA 2024 Global Annual Meeting

History converged with the future at DIA’s 60th-anniversary Global Annual Meeting. The conference’s theme—Charting New Horizons—fit the mood perfectly. The palpable energy and high attendance levels were reminiscent of pre-pandemic times; it felt like we finally put COVID-19 behind us. Still, underlying this return to “normal” was an eagerness not to forget the lessons of…

Explore

June 20, 2024

DE&I and Drug Safety: Surprising Connections to Improve Patient Health

Diversity, Equity, and Inclusion (DE&I) and drug safety in clinical trials teams may not have established relationships within an organization. Yet, these two areas of focus have more similarities than one might think. In our next installment of our series on our Interpretation of Pharmacovigilance Guidances and Regulations Initiative (IGR PV), we are exploring this…

Explore

March 22, 2024

Inspiring Inclusion: The Power of Pivotal Moments 

This year, TransCelerate honored International Women’s Day, and the theme of “inspiring inclusivity” by gathering a panel of distinguished thought leaders within biopharma R&D for a discussion on “Inspiring Inclusion: The Power of Pivotal Moments.”  TransCelerate COO Allison Cuff Shimooka moderated the event. Panelists were Esther Krofah (Milken Institute Health), Joni Rutter (NCATS/NIH), Janet Woodcock…

Explore

February 22, 2024

SCOPE Summit 2024: Modernizing and Personalizing Clinical Trials  

SCOPE 2024 kicked off with 4,000 attendees traveling to Orlando, Florida, for the much-anticipated event. Common themes shared across all sessions include the importance of collaboration, focusing on patients and their caregivers, and avoiding a “one size fits all” approach to designing clinical trials. Read on for the highlights from TransCelerate’s seven sessions.   The conference…

Explore

December 5, 2023

Operationalizing Patient Safety: An Overview of TransCelerate’s Interpretation of PV Guidances & Regulations Initiative

For the second installment of our Interpretation of Pharmacovigilance Guidances & Regulations (IGR PV) Initiative blog series, we will take a deep dive into the initiative and its goals. Established in 2018, this initiative germinated when it became apparent that some of the regulations issued by global Health Authorities can be unclear and/or challenging for…

Explore

October 17, 2023

Digital Data Flow Discovery Day: The “Art of the Possible”

On the eve of this year’s DPharm conference, TransCelerate hosted its first Digital Data Flow Discovery Day in Boston. The goal of the event was to raise awareness, exchange knowledge, and convene stakeholders from around the R&D industry to demonstrate the implementation of its Digital Data Flow (DDF) solutions, the Unified Study Definitions Model (USDM),…

Explore